MX2019003007A - 1-arilnaftiridin-3-carboxamidas 7-sustituidas y su uso. - Google Patents

1-arilnaftiridin-3-carboxamidas 7-sustituidas y su uso.

Info

Publication number
MX2019003007A
MX2019003007A MX2019003007A MX2019003007A MX2019003007A MX 2019003007 A MX2019003007 A MX 2019003007A MX 2019003007 A MX2019003007 A MX 2019003007A MX 2019003007 A MX2019003007 A MX 2019003007A MX 2019003007 A MX2019003007 A MX 2019003007A
Authority
MX
Mexico
Prior art keywords
naphthyridine
aryl
substituted
carboxylic acid
acid amides
Prior art date
Application number
MX2019003007A
Other languages
English (en)
Inventor
Marquardt Tobias
Teller Henrik
Vakalopoulos Alexandros
Tinel Hanna
Mondritzki Thomas
Straub Alexander
Brechmann Markus
Andreas Kullmann Maximilian
Freudenberger Till
Boultadakis Arapinis Melissa
Beat Wittwer Matthias
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16188728.6A external-priority patent/EP3296298A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX2019003007A publication Critical patent/MX2019003007A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente solicitud se refiere a nuevas 1-arilnaftiridin-3-carbo xamidas 7-sustituidas, a procesos para su preparación, a su uso, solas o en combinaciones, para el tratamiento y/o prevención de enfermedades y a su uso para la producción de medicamentos para el tratamiento y/o prevención de enfermedades, en particular para el tratamiento y/o la prevención de trastornos cardiovasculares y/o trastornos renales.
MX2019003007A 2016-09-14 2017-09-06 1-arilnaftiridin-3-carboxamidas 7-sustituidas y su uso. MX2019003007A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16188728.6A EP3296298A1 (de) 2016-09-14 2016-09-14 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung
EP16202509 2016-12-06
PCT/EP2017/072339 WO2018050510A1 (de) 2016-09-14 2017-09-06 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung

Publications (1)

Publication Number Publication Date
MX2019003007A true MX2019003007A (es) 2019-07-18

Family

ID=59966701

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003007A MX2019003007A (es) 2016-09-14 2017-09-06 1-arilnaftiridin-3-carboxamidas 7-sustituidas y su uso.

Country Status (40)

Country Link
US (3) US10927109B2 (es)
EP (1) EP3512849B1 (es)
JP (1) JP7295019B2 (es)
KR (2) KR20230035437A (es)
CN (4) CN109689656B (es)
AU (1) AU2017326297B2 (es)
BR (1) BR112019004982A2 (es)
CA (1) CA3036497A1 (es)
CL (1) CL2019000670A1 (es)
CO (1) CO2019002361A2 (es)
CR (1) CR20190131A (es)
CU (1) CU24618B1 (es)
CY (1) CY1124492T1 (es)
DK (1) DK3512849T3 (es)
DO (1) DOP2019000060A (es)
EC (1) ECSP19018116A (es)
ES (1) ES2887674T3 (es)
GE (1) GEP20217332B (es)
HR (1) HRP20211396T1 (es)
HU (1) HUE056343T2 (es)
IL (1) IL265106B (es)
JO (1) JOP20190045A1 (es)
LT (1) LT3512849T (es)
MA (1) MA46235B1 (es)
MX (1) MX2019003007A (es)
MY (1) MY196473A (es)
NI (1) NI201900023A (es)
NZ (1) NZ751297A (es)
PE (1) PE20190803A1 (es)
PH (1) PH12019500535A1 (es)
PL (1) PL3512849T3 (es)
RS (1) RS62299B1 (es)
SG (1) SG11201901973RA (es)
SI (1) SI3512849T1 (es)
TN (1) TN2019000083A1 (es)
TW (1) TWI758325B (es)
UA (1) UA125627C2 (es)
UY (1) UY37403A (es)
WO (1) WO2018050510A1 (es)
ZA (1) ZA201902325B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20170158A7 (es) 2015-06-09 2018-06-05 Bayer Pharma AG Derivados sustituidos de 1-arilnaftiridina-3-carboxamidas y su utilidad en el tratamiento o prevención de enfermedades cardiovasculares y renales
CN109689654A (zh) 2016-07-11 2019-04-26 拜耳医药股份有限公司 7-取代的1-吡啶基-萘啶-3-甲酰胺类及其用途
JOP20190045A1 (ar) * 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
JP2023521783A (ja) * 2020-04-08 2023-05-25 バイエル、アクチエンゲゼルシャフト Ｒｔ－ｐｃｒを用いたウイルス感染の迅速な検出

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
JPS60228479A (ja) 1984-04-26 1985-11-13 Toyama Chem Co Ltd １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩
DE3508816A1 (de) 1985-01-10 1986-07-10 Bayer Ag, 5090 Leverkusen 6,7-disubstituierte 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphtyridin-3-carbonsaeuren
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
DE4301246A1 (de) 1993-01-19 1994-07-21 Bayer Ag Chinolon- und Naphthyridoncarbonsäurederivate
WO1995005373A1 (en) * 1993-08-13 1995-02-23 Dong Wha Pharmaceutical Industrial Co., Ltd. Novel quinolone carboxylic acid derivatives
DE69724140T2 (de) 1996-11-28 2004-06-03 Wakunaga Pharmaceutical Co., Ltd. Pyridoncarbonsäurederivate oder ihre salze und diese als aktive bestandteile enthaltende medikamente
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6964966B2 (en) 2001-04-25 2005-11-15 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
EP1453824A1 (en) 2001-12-13 2004-09-08 Wockhardt Limited New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP2005012561A (ja) 2003-06-19 2005-01-13 Sony Corp 画像処理装置、画像処理方法および画像投射装置
CA2530352A1 (en) 2003-07-24 2005-02-03 Astellas Pharma Inc. Quinolone derivative or salt thereof
WO2005026145A2 (en) 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinolone antibacterial agents
WO2005026165A1 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinolone antibacterial agents
DE10343098A1 (de) 2003-09-18 2005-04-14 Bayer Healthcare Ag Tetrahydrochinoxaline und ihre Verwendung
WO2005049602A1 (en) 2003-11-18 2005-06-02 Warner-Lambert Company Llc Quinolone antibacterial agents
RU2006124559A (ru) 2003-12-09 2008-01-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Производные нафтиридина и применение указанных производныхых в качестве модуляторов мускариновых рецепторов
WO2007056113A2 (en) * 2005-11-02 2007-05-18 Cylene Pharmaceuticals, Inc. Methods for targeting quadruplex sequences
WO2010093341A1 (en) * 2009-02-10 2010-08-19 Janssen Pharmaceutica N.V. C-7 isoxazolinyl quinolone/naphthyridine derivatives useful as antibacterial agents
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
EP2512243B1 (en) 2009-12-17 2016-04-06 Merck Sharp & Dohme Corp. Quinoline amide m1 receptor positive allosteric modulators
RS56312B1 (sr) 2010-02-27 2017-12-29 Bayer Ip Gmbh Ariltriazoloni spojeni sa bis-arilom i njihova upotreba
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2708539A1 (de) 2010-07-09 2014-03-19 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
CN103360388B (zh) 2012-04-10 2017-11-14 江苏先声药业有限公司 5‑氨基‑1，4‑二氢‑1，8‑萘啶衍生物及其药物组合物和用途
CN102964350A (zh) 2012-09-20 2013-03-13 杨文� 一种7-六氢吡咯并[1,2-a]吡嗪基喹诺酮羧酸衍生物及其在治疗幽门螺杆菌感染应用
CN103183676B (zh) 2013-03-12 2015-04-08 中国医学科学院医药生物技术研究所 一组1-取代-1,8萘啶甲酰胺衍生物及制备和应用
GB201409044D0 (en) 2014-05-21 2014-07-02 Ucl Business Plc New compounds
MA40893B1 (fr) 2014-11-03 2018-11-30 Bayer Pharma AG Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
EP3221295B1 (en) 2014-11-17 2021-04-14 Nirogy Therapeutics, Inc. Monocarboxylate transport modulators and uses thereof
CU20170158A7 (es) 2015-06-09 2018-06-05 Bayer Pharma AG Derivados sustituidos de 1-arilnaftiridina-3-carboxamidas y su utilidad en el tratamiento o prevención de enfermedades cardiovasculares y renales
MX2017016013A (es) 2015-06-09 2018-04-20 Je Il Pharmaceutical Co Ltd Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo.
PE20230683A1 (es) 2015-06-09 2023-04-21 Abbvie Inc Moduladores de receptor nuclear
CN109689654A (zh) 2016-07-11 2019-04-26 拜耳医药股份有限公司 7-取代的1-吡啶基-萘啶-3-甲酰胺类及其用途
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.

Also Published As

Publication number Publication date
JP2019534320A (ja) 2019-11-28
BR112019004982A2 (pt) 2019-08-20
SI3512849T1 (sl) 2021-10-29
UY37403A (es) 2018-04-30
US20210261541A1 (en) 2021-08-26
CL2019000670A1 (es) 2019-08-02
US11472803B2 (en) 2022-10-18
DK3512849T3 (da) 2021-08-16
HRP20211396T1 (hr) 2021-12-10
CN109689656A (zh) 2019-04-26
PE20190803A1 (es) 2019-06-10
AU2017326297B2 (en) 2021-07-29
CY1124492T1 (el) 2022-07-22
MA46235A (fr) 2021-04-14
CU24618B1 (es) 2022-08-09
RS62299B1 (sr) 2021-09-30
CN115477649A (zh) 2022-12-16
KR20230035437A (ko) 2023-03-13
CR20190131A (es) 2019-05-15
TWI758325B (zh) 2022-03-21
NZ751297A (en) 2022-12-23
CU20190020A7 (es) 2019-11-04
DOP2019000060A (es) 2019-04-15
JP7295019B2 (ja) 2023-06-20
WO2018050510A1 (de) 2018-03-22
CN109689656B (zh) 2022-10-04
TN2019000083A1 (en) 2020-07-15
CN115554294A (zh) 2023-01-03
US20190263805A1 (en) 2019-08-29
ZA201902325B (en) 2022-03-30
ECSP19018116A (es) 2019-03-29
SG11201901973RA (en) 2019-04-29
MA46235B1 (fr) 2021-10-29
CO2019002361A2 (es) 2019-06-19
PH12019500535A1 (en) 2019-11-04
LT3512849T (lt) 2021-08-25
KR20190046851A (ko) 2019-05-07
US20220089591A1 (en) 2022-03-24
EP3512849B1 (de) 2021-06-23
TW201811785A (zh) 2018-04-01
HUE056343T2 (hu) 2022-02-28
CN115429798A (zh) 2022-12-06
PL3512849T3 (pl) 2021-11-29
UA125627C2 (uk) 2022-05-04
IL265106B (en) 2022-05-01
CA3036497A1 (en) 2018-03-22
EP3512849A1 (de) 2019-07-24
AU2017326297A1 (en) 2019-03-28
JOP20190045A1 (ar) 2019-03-14
NI201900023A (es) 2019-05-23
MY196473A (en) 2023-04-12
US10927109B2 (en) 2021-02-23
ES2887674T3 (es) 2021-12-27
GEP20217332B (en) 2021-12-10

Similar Documents

Publication Publication Date Title
PH12018500057A1 (en) Substituted oxopyridine derivatives
TN2015000434A1 (en) Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
PH12016502015A1 (en) Anti-factor d antibody variants and uses thereof
MX2017004510A (es) Triazolopirazinonas como inhibidores de pde1.
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
PH12017501990A1 (en) Imidazopyrazinones as pde1 inhibitors
WO2016046156A8 (de) Substituierte oxopyridin-derivate
MX2018005233A (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
PH12016500525A1 (en) Substituted phenylalanine derivatives
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
EA202191301A1 (ru) СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
MX2016000037A (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
PH12019502315A1 (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
MX2019012153A (es) N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso.
PH12017501693A1 (en) Compositions for the treatment of kidney and/or liver diseases
TN2015000523A1 (en) Substituted benzoxazoles